Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
Cyclodextrins have not been popular excipients for nasal or pulmonary drug delivery so far. This can change soon, with the
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
The smallest possible cyclodextrins were synthesized by Japanese scientists. They are the first new small cyclodextrins since 1994 when the synthesis of the five membered cyclodextrin was described.